The Black Swan Research Initiative® and a Paradigm Shift in the Treatment of Multiple Myeloma
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
Clinical Pearls
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
- Many investigators are interested in the Black Swan Research Initiative to study minimal residual disease (MRD) or to study treatments that could achieve MRD-Zeroâ„¢
- Durie believes the time is right to not just compare treatments for multiple myeloma but to see if the disease is curable
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
